Japan’s Consumer Affairs Agency oversees multiple functions including developing, assessing, and scrutinizing consumer policies which safeguards against fraudulent business practices and false labeling while establishing necessary labeling standards that are understandable to consumers.

The claims which have been accepted for Lutemax 2020 include eye health (Macular Pigment Optical Density [MPOD]), reduced eye fatigue, and improved visual performance (contrast sensitivity, glare recovery), as well as supporting sleep quality.

“With over 65,000 people over the age of 100, Japan is the country with the largest percentage of centenarians in the world. Coupled with the rise in digital screen usage and exposure to blue light across all ages globally, there is a need to supply Japanese consumers with a premium, clinically-tested eye health ingredient, which helps them support healthy vision for a lifetime,” said Brian Appell, Marketing Manager, OmniActive Health Technologies.

“Gaining SR approval in Japan for Lutemax 2020 allows just that as well as delivers manufactures a clear and easy way to communicate scientifically supported eye health benefits to consumers and differentiate in this key market.”

After what the company says was a rigorous systematic review (SR) of scientific evidence by Japan’s Consumer Affairs Agency, OmniActive Health Technologies’ Lutemax 2020 Lutein and Zeaxanthin Isomers has obtained Foods with Function Claims (FFC) approval.

-----------------------------------------------------------------------
Editors Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.